- Home
- ACR vs KOD Comparison
ACR vs KOD Comparison
Compare ACR & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACR | KOD |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.2M | 795.5M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | ACR | KOD |
|---|---|---|
| Price | $23.53 | $27.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $24.50 | $22.67 |
| AVG Volume (30 Days) | 50.4K | ★ 890.8K |
| Earning Date | 10-29-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.65 | N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $88,952,000.00 | N/A |
| Revenue This Year | $4.05 | N/A |
| Revenue Next Year | $0.38 | N/A |
| P/E Ratio | $24.35 | ★ N/A |
| Revenue Growth | ★ 14.87 | N/A |
| 52 Week Low | $15.35 | $1.92 |
| 52 Week High | $24.61 | $29.49 |
Technical Indicators
Market Signals| Indicator | ACR | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 50.90 | 63.00 |
| Support Level | $23.48 | $25.44 |
| Resistance Level | $24.61 | $29.49 |
| Average True Range (ATR) | 0.94 | 2.07 |
| MACD | -0.09 | 0.15 |
| Stochastic Oscillator | 36.60 | 70.71 |
Price Performance
Historical ComparisonAbout ACR ACRES Commercial Realty Corp.
ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralize debt obligations, and private equity investments mainly issued by financial institutions.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.